Raymond James Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Raymond James Trust’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$234K	Sell	3,199 -16	-0.5%	-$1.2K	0.01%	1168
2024 Q2	$220K	Sell	3,215 -194	-6%	-$13.5K	0.01%	1147
2024 Q1	$236K	Buy	3,409 +287	+9%	+$19.7K	0.01%	1109
2023 Q4	$224K	Buy	+3,122	New	+$180K	0.01%	1088
2023 Q3	–	Sell	-3,248	Closed	-$206K	–	1217
2023 Q2	$206K	Buy	+3,248	New	+$202K	0.01%	1099
2022 Q4	–	Sell	-4,467	Closed	-$208K	–	1172
2022 Q3	$208K	Buy	4,467 +106	+2%	+$5.54K	0.01%	975
2022 Q2	$249K	Sell	4,361 -215	-5%	-$12.2K	0.01%	905
2022 Q1	$280K	Sell	4,576 -767	-14%	-$39.8K	0.01%	920
2021 Q4	$280K	Buy	+5,343	New	+$224K	0.01%	933
2021 Q3	–	Sell	-4,933	Closed	-$201K	–	1174
2021 Q2	$201K	Buy	+4,933	New	+$182K	0.01%	1067

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Trust's ITCI Position: Q3 2024 in Review

Raymond James Trust reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 0.5% in Q3 2024, selling an estimated $1.2K and leaving 3,199 shares worth $234K. The position accounts for 0.01% of the portfolio, ranked #1168.

Raymond James Trust first reported a position in ITCI in Q2 2021 and has held it in 10 quarters since. The position peaked at $280K in Q1 2022. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Raymond James Trust held 3,199 shares of Intra-Cellular Therapies Inc. worth $234K as of Q3 2024.
Raymond James Trust sold 16 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $1.2K.
Intra-Cellular Therapies Inc. made up 0.01% of Raymond James Trust's portfolio in Q3 2024, its #1168 holding.
Raymond James Trust first reported a position in Intra-Cellular Therapies Inc. in Q2 2021 and has held it in 10 quarters since.
Raymond James Trust's Intra-Cellular Therapies Inc. position peaked at $280K in Q1 2022.
355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.